A Global Medical Device Manufacturer Focused on the Aesthetic, Plastic and Reconstructive Surgery Industry

Transcription

1 Setember 28, 2006

2 Safe Harbor In addition to historical information, this resentation contains forward-looking statements. Such statements are based uon the current beliefs and exectations of MediCor s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the accetability to regulators of our regulatory data and submissions; the ability to obtain governmental arovals to market our roducts; the timing of our and our cometitors arovals and entry to markets; the effect of such timing and the related delays in revenues and continued exenses and their affect on our ability to successfully and rofitably oerate our businesses; increased cometition and its effect on ricing, sending, third-arty relationshis and revenues; the risk that businesses we acquire will not be integrated or oerated successfully; the risk that cost savings or other anticiated benefits from acquisition transactions may not be realized or may take longer to realize than exected; disrution from transactions making it more difficult to maintain relationshis with customers, emloyees or suliers; the outcome of legal roceedings; the risk of new and changing regulations in the U.S. and internationally; the risk of instability in the caital markets in the U.S. and internationally; and the ability to obtain requisite financing for continuing oerations or for acquisitions to continue to execute on our growth lans. Additional factors that could cause MediCor s results to differ materially from those described in the forward-looking statements can be found in MediCor s Annual Reort on Form 10-KSB for the year ended June 30, 2006, which has been filed with the Securities and Exchange Commission and is available at the Securities and Exchange Commission s Internet site (htt:// The Comany takes no obligation to udate any forward-looking statements included herein.

3 Oortunity A Global Medical Device Manufacturer Focused on the Aesthetic, Plastic and Reconstructive Surgery Industry Founded and led by industry ioneer Donald K. McGhan Substantial invested caital by management Significant international resence Two breast imlant roducts ositioned to enter the U.S. market Innovative new roduct develoment ieline

4 Fundamentals A Global Global Medical Medical Device Device Manufacturer Manufacturer Focused Focused on on the the Aesthetic, Aesthetic, Plastic Plastic and and Reconstructive Reconstructive Surgery Surgery Industry Industry Fiscal year ended June 30, 2006: 21 Million shares issued and outstanding $31 Million revenue Over 12.5 million shares owned or controlled by Executive Management and Directors Current aroximate annual revenue of $40 million

5 Senior Management Donald K. McGhan, Founder and Chairman Industry Pioneer - 40 years exerience Founder of Inamed Cororation (Acquired by Allergan) Develoed Mentor Cororation s lastic surgery roduct line Theodore R. Maloney, Chief Executive Officer and Director Since years legal exerience 10 years working with various Inamed/McGhan entities Jim J. McGhan, Chief Oerating Officer and Director Former COO of Inamed/Allergan Develoed Inamed/Allergan s Class III medical devices Develoed LAP BAND Adjustable Gastric Banding System Paul R. Kimmel, Chief Financial Officer CFO of MediCor since March 2006 Former VP, Finance of Inamed/Allergan; former VP and Controller of Inamed/Allergan MBA from Harvard Graduate School of Business Administration; Certified Public Accountant

6 Cororate History Founded by Donald K. McGhan Acquired North American distribution rights to Poly Imlants Protheses ( PIP-France ) re-filled saline breast imlants Entered into U.S. Food and Drug Administration ( FDA ) clinical trials Acquired HPL Biomedical Inc. dba Biodermis Scar management and ost-oerative care roducts Acquired North American distribution rights to Biosil/Nagor inflatable breast imlants Acquired Eurosilicone SAS breast imlant manufacturer based in France Acquired the atent for an alternative breast imlant fill material Raised $50 million senior secured notes and warrants Acquired Biosil/Nagor - breast imlant manufacturer and marketing comany based in the UK

7 Global Breast Imlant Market $772 Million Market* Average 20% CAGR since 2004 $1,400 $1,304 $1,200 $1,092 $1,000 $916 $800 $772 ($mm) $600 $524 $637 $400 $200 $ *Estimate for

8 U.S. Breast Imlant Market Historic Procedures Increased seven fold in 10 years Over 364,000 rocedures in 2005 Over 11% CAGR from 1999 to % Growth rate from Total Breast Augmentation Procedures in the United States 400, , , , , , ,000 50, , , , , , , ,583 CAGR Source: American Society of Aesthetic Plastic Surgeons

9 Breast Imlant Market Overview Inamed/Allergan Mentor MediCor 2005 Worldwide Breast Imlant Sales Mix Other 7% 12% 42% 39%

10 Eurosilicone: Key Business Considerations Based in France, manufacturer and marketer of breast imlants and related roducts. High quality reutation, with sales rimarily in Latin America and Euroe. Acquired in July 2004 Restructured distribution network Shifting from 100% distributor-based sales Direct sales efforts underway in major markets Unit roduction caacity u 133% Significant imrovements to Regulatory and Quality Assurance Programs ISO-certified manufacturing facilities

11 Biosil/Nagor: Key Business Considerations UK-based Nagor Limited and Biosil Limited s breast imlants and related roducts have a high quality, well-established reutation, rimarily in Euroe. Acquired in Aril 2006 Purchase Price: Arox. $41 million Combination cash and stock GMP-insected and ISO-certified facilities Vertically integrated Positioned for U.S. PMA aroval

12 Eurosilicone: Breast Imlant Products Full roduct offering of: Textured and smooth High-consistency and traditional silicone gel-filled Round and anatomical Cometitive advantages: Wide base to create a natural look Unique barrier coat shell Reduces gel bleed and fill migration Micro-textured shells Excellent biocomatibility, reduced casular contracture International sales - aroximately 97% silicone gel, 3% saline-filled imlant

13 Biosil: Breast Imlant Products Full roduct offering: Textured and smooth shells High-consistency and traditional silicone gel-filled imlants Round and anatomical Cometitive advantages: Unique hysical characteristics of the Biosil silicone - a softer, more liable feel Inflatable saline-filled imlant ositioned for U.S. entry Pre-Market Aroval ( PMA ) alication being reared for submission to the FDA Arox. 98% silicone gel-filled imlants outside the U.S. Anticiated U.S. PMA Clearance

14 Poly Imlants Protheses (PIP-France) Pre-filled Saline Imlants Exclusive North American distribution Cometitive advantages: Otimum filling Ease of insertion Reduced surgical time Softer, more sule shell MediCor owns the PMA Anticiated U.S. PMA clearance

15 Current Products and Product Pieline Commercial Distribution Distribution Rights PMA Rights Intellectual Proerty International Silicone Breast Imlants (Eurosilicone) Current commercial international sales Silicone Breast Imlants (Biosil) Current commercial international sales Inflatable Saline Filled Breast Imlants (Biosil/Nagor) Anticiated U.S. PMA Pre-filled Saline Breast Imlants (PIP- France) Anticiated U.S. PMA Scar Management Products (Biodermis) Current sales Alternative Fill Imlants Anticiated worldwide sales

16 Alternative Fill Breast Imlants MediCor owns the atents for alternative fill materials in the breast imlant market Unique oortunity for substantial cometitive advantages/roduct differentiation: Radiolucence Silicone and saline are radio-oaque Allows X-ray enetration eliminates the difficult/ainful Mammograhy techniques Silicone gel-like feel Viscous material Perceived safety associated with saline Naturally excreted in the event of ruture Anticiated commercialization worldwide

17